Skip to Content
Merck
CN

533734

1,3-Propanediol

≥99.6%

Synonym(s):

1,3-Dihydroxypropane, Trimethylene glycol

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
HO(CH2)3OH
CAS Number:
Molecular Weight:
76.09
EC Number:
207-997-3
UNSPSC Code:
12162002
PubChem Substance ID:
Beilstein/REAXYS Number:
969155
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


vapor pressure

0.8 mmHg ( 20 °C), 9.8 mmHg ( 100 °C)

assay

≥99.6%

impurities

<0.1% water

refractive index

n20/D 1.440 (lit.)

surface tension

46.2 dyn/cm, 20 °C

viscosity

52 cP(20 °C)(lit.)

bp

214 °C/760 mmHg (lit.)

mp

−27 °C (lit.)

solubility

H2O: soluble

density

1.053 g/mL at 25 °C (lit.)

anion traces

chloride (Cl-): <0.5 ppm

SMILES string

OCCCO[H]

InChI

1S/C3H8O2/c4-2-1-3-5/h4-5H,1-3H2

InChI key

YPFDHNVEDLHUCE-UHFFFAOYSA-N

Application

For applications, see P5040-4


Still not finding the right product?

Explore all of our products under 1,3-Propanediol


Storage Class

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



E Celińska
Biotechnology advances, 28(4), 519-530 (2010-04-07)
The history of 1,3-propanediol (1,3-PD) conversion from being a specialty chemical to being a bulk chemical illustrates that the concerted effort of different metabolic engineering approaches brings the most successful results. In order to metabolically tailor the 1,3-PD production pathway
Sarbjit S Saini et al.
The Journal of investigative dermatology, 135(1), 67-75 (2014-07-22)
ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at
Ryosuke Kikuchi et al.
Nature medicine, 20(12), 1464-1471 (2014-11-05)
Peripheral artery disease (PAD) generates tissue ischemia through arterial occlusions and insufficient collateral vessel formation. Vascular insufficiency in PAD occurs despite higher circulating levels of vascular endothelial growth factor A (VEGF-A), a key regulator of angiogenesis. Here we show that